analytics / biologic
Analytical Basics for Biologics
April Stanley, MS MBA
Nice Insight
NI-8-26-MA37Sep 15, 2026
E. coli
Biomanufacturing with E. coli
April Stanley, MS MBA
Nice Insight
NI-8-26-MA9Sep 15, 2026
Single-Use
The Changing Economics of Single-Use Biomanufacturing
Pharma's Almanac
PAO-09-26-PA-08Sep 10, 2026
Productivity
The Next Productivity Leap in Mammalian Cell Culture
Pharma's Almanac
PAO-09-26-PA-03Sep 3, 2026
Capacity
Is the Bioreactor Arms Race Over?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-01Sep 1, 2026
antibodies
Key Technologies Used in Manufacturing Antibodies
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA11Aug 28, 2026
Market Drivers
Global Antibody-Drug Conjugate (ADC) Market Trends
April Stanley, MS MBA
Nice Insight
NI-8-26-MA-16Aug 26, 2026
Market Drivers
Global Biopharmaceutical Market Trends
April Stanley, MS MBA
Nice Insight
NI-8-26-MA18Aug 26, 2026
Market Drivers
Market Drivers of Biologics
April Stanley, MS MBA
Nice Insight
NI-8-26-MA17Aug 25, 2026
Prevention
Preventive Therapeutics Beyond Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-13Aug 18, 2026
Critical Materials
Securing Critical Materials for Resilient Biopharmaceutical Manufacturing
Pharma's Almanac
PAO-08-26-PA-04Aug 6, 2026
Vaccines
The Next Generation of Vaccine Platforms
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-01Aug 3, 2026
AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19Jul 20, 2026
Drug–Device
Designing Formulations Around Devices Rather Than Vice Versa
Pharma's Almanac
PAO-07-26-PA-04Jul 7, 2026
Protein Conformation
Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-17Jul 6, 2026
Cell-Free Synthesis
Cell-Free Biomanufacturing and the Future of Flexible Biologics Production
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-24Jun 15, 2026
Protein Engineering
Exponential Advances in Protein Engineering
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-26-PA-04Jun 8, 2026
BsAbs
Why Bispecific Antibody Architecture Is a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-01Jun 2, 2026
High-Concentration
Impact of High Concentration Antibody Products on Formulation and Manufacturing
April Stanley, MS MBA; Amelia Hepworth
Nice Insight
NI-06-26-03Jun 1, 2026
Biomanufacturing
Biomanufacturing with E. coli
April Stanley, MS MBA
Nice Insight
NI-06-26-02Jun 1, 2026